Ultragenyx Pharmaceutical Inc.
RAREHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeUltragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare. At a $1.54B market cap, Ultragenyx Pharmaceutical Inc. ranks as a small-cap company within healthcare. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for the treatment of long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
Market Cap
$1.54B
Beta
0.35
P/E (TTM)
—
P/E (Fwd)
69.37
EPS (TTM)
$-5.82
EPS (Fwd)
$0.23
ROE
—
ROA
-24.2%
Cash
$292.0M
Total Debt
$1.20B
Free CF
-$221.8M
52W Change
-55.7%
Annual Financials
Cash vs Debt
Where RARE stands vs its 150-day and 200-day moving averages
As of the September 25, 2026 close, RARE finished 38.74% below its 150-day moving average ($24.11) and 40.27% below its 200-day moving average ($24.73). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RARE overbought or oversold?
At the September 25, 2026 close, RARE's RSI(14) was 49.4, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Ultragenyx Pharmaceutical Inc. carries $1.20B in total debt against $292.0M in cash reserves — debt is roughly 4.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$221.8M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Revenue has grown from $363.3M (2022) to $673.0M (2025), reflecting a 85% increase over the period.
With a beta below 0.7, Ultragenyx Pharmaceutical Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Ultragenyx Pharmaceutical Inc.'s trajectory.